Search results
Crinecerfont Promising for Congenital Adrenal Hyperplasia
Medscape· 5 days agoCrinecerfont, an investigational oral selective corticotropin-releasing factor type 1 receptor...
Crinetics Unveils 'Stunning' Results In Highly Anticipated Study
Investor's Business Daily· 4 days agoCrinetics unveiled "stunning" results Monday from a study of a drug that tamps down on levels of a...
Neurocrine's Crinecerfont shows promise in CAH Phase 3 trial By Investing.com
Investing.com· 4 days ago(NASDAQ:NBIX) announced today that its CAHtalyst™ Adult Phase 3 study has met its primary and key...
Crinetics shares maintain price target, Overweight rating on positive trial data By Investing.com
Investing.com· 3 days ago(NASDAQ:CRNX), following the presentation of encouraging trial data. The company, at the ENDO 2024...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 4 days agoNeurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine PR Newswire SAN DIEGO, June 3, 2024 - CAHtalyst™ Pediatric
Nano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major...
Benzinga via Yahoo Finance· 3 days agoHealth GmbH have collaborated to develop Spruce’s investigational product candidate, tildacerfont,...
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
Investor's Business Daily· 7 days agoThe company is a leader in the neuroscience space. Neurocrine recently asked the FDA to approve...
RBC maintains Perform rating on Neurocrine Bio shares By Investing.com
Investing.com· 1 day agoOn Thursday, RBC Capital maintained its Sector Perform rating on Neurocrine (NASDAQ:NBIX)...
Science explains why bearded ladies are so common – but history has treated them cruelly
The Telegraph via Yahoo News· 5 days ago‘You should be women,” says a terrified Banquo when he and Macbeth meet the witches conjuring spells...
BridgeBio Pharma (NASDAQ:BBIO) Stock Rating Reaffirmed by HC Wainwright
ETF DAILY NEWS· 1 day agoHC Wainwright restated their buy rating on shares of BridgeBio Pharma (NASDAQ:BBIO – Free Report) in a report issued on Wednesday, Benzinga reports. HC Wainwright currently has a $43.00 price ...